PD-(L)1 x VEGF developments coinciding with ASCO overshadowed the conference proper.

Roche dumps another partnered asset.

BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.

Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.

LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.

Bristol buys into the frenzy, and VEGF bispecific value inflation continues.